A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer

The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4–ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is...

Descripción completa

Detalles Bibliográficos
Autores principales: Esfahani, Khashayar, Agulnik, Jason Scott, Cohen, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104550/
https://www.ncbi.nlm.nih.gov/pubmed/25101240
http://dx.doi.org/10.3389/fonc.2014.00174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104550/
https://www.ncbi.nlm.nih.gov/pubmed/25101240
http://dx.doi.org/10.3389/fonc.2014.00174

Ejemplares similares